TY - JOUR
T1 - Clinical characteristics and treatment outcomes among respiratory syncytial virus (RSV)-infected hematologic malignancy and hematopoietic stem cell transplant recipients receiving palivizumab
AU - Permpalung, Nitipong
AU - Mahoney, Monica V.
AU - McCoy, Christopher
AU - Atsawarungruangkit, Amporn
AU - Gold, Howard S.
AU - Levine, James D.
AU - Wong, Michael T.
AU - LaSalvia, Mary T.
AU - Alonso, Carolyn D.
N1 - Publisher Copyright:
© 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2019/1/2
Y1 - 2019/1/2
N2 - Palivizumab has been used to treat respiratory syncytial virus (RSV)-infected hematologic malignancy patients at our institution based on limited published data. We conducted this retrospective study to evaluate clinical outcomes and mortality rates of RSV-infected hematologic malignancy patients from 2007 to 2016. A total of 67 patients (19 received palivizumab and 47 received supportive care) were identified. Palivizumab-treated patients had a significantly higher proportion of underlying ischemic heart disease, graft-versus-host-disease, hypogammaglobulinemia, and concomitant pulmonary infections. There were no significant differences in mortality rates or readmission rates between the two groups. The estimated odds ratio for death in patients receiving palivizumab after adjusting for propensity scores and covariates were 0.12 ([0.01, 1.32], p =.08) and 0.09 ([0.01, 1.03], p =.05) respectively. After adjustment for factors associated with severity of illness, there was no difference in mortality among patients treated with palivizumab.
AB - Palivizumab has been used to treat respiratory syncytial virus (RSV)-infected hematologic malignancy patients at our institution based on limited published data. We conducted this retrospective study to evaluate clinical outcomes and mortality rates of RSV-infected hematologic malignancy patients from 2007 to 2016. A total of 67 patients (19 received palivizumab and 47 received supportive care) were identified. Palivizumab-treated patients had a significantly higher proportion of underlying ischemic heart disease, graft-versus-host-disease, hypogammaglobulinemia, and concomitant pulmonary infections. There were no significant differences in mortality rates or readmission rates between the two groups. The estimated odds ratio for death in patients receiving palivizumab after adjusting for propensity scores and covariates were 0.12 ([0.01, 1.32], p =.08) and 0.09 ([0.01, 1.03], p =.05) respectively. After adjustment for factors associated with severity of illness, there was no difference in mortality among patients treated with palivizumab.
KW - Respiratory syncytial virus
KW - hematologic malignancy
KW - hematopoietic stem cell transplantation
KW - palivizumab
UR - http://www.scopus.com/inward/record.url?scp=85049152954&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85049152954&partnerID=8YFLogxK
U2 - 10.1080/10428194.2018.1468896
DO - 10.1080/10428194.2018.1468896
M3 - Article
C2 - 29947555
AN - SCOPUS:85049152954
SN - 1042-8194
VL - 60
SP - 85
EP - 91
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 1
ER -